Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving patient-centricity and efficiency in clinical trial design.

FAIR Health released the second edition of the Monthly Telehealth Regional Tracker Trending Reports, a free set of infographics that show national and regional trends in telehealth from July to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...